Egrifta market seen growing on HIV-linked demand and specialty drug trends

The Business Research Company says the global Egrifta (tesamorelin acetate) market is set to expand through 2035 as HIV-associated lipodystrophy cases rise and specialty peptide therapies gain traction. North America is expected to lead the market in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - Egrifta targets HIV-associated lipodystrophy, a condition tied to excess abdominal fat and long-term antiretroviral therapy. - The market outlook points to continued demand for therapies that improve body composition and quality of life for people living with HIV. - The report frames tesamorelin acetate as part of a broader shift toward personalized HIV care and peptide-based treatments.

What happened: - The Business Research Company published its “Egrifta (Tesamorelin Acetate) Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035.” - The report says the historical market expansion was driven by higher cases of HIV-associated lipodystrophy, clinical support for growth hormone-releasing hormone analogs and growing awareness of visceral fat risks. - The report also says the forecast period will be shaped by personalized HIV care, a broader peptide therapy pipeline, better diagnosis of metabolic complications and favorable reimbursement for specialty drugs. - The company released a free sample and the full report online: the market report sample and the full market report.

The details: - Egrifta, or tesamorelin acetate, is a synthetic peptide designed to reduce excess abdominal fat in HIV patients with lipodystrophy. - The drug works by mimicking growth hormone-releasing hormone and stimulating growth hormone release. - The report says the mechanism helps break down visceral fat, improve fat distribution and reduce health risks linked to abdominal fat accumulation. - The report identifies emerging trends including long-acting peptide treatments, personalized lipodystrophy management, broader metabolic uses, patient-focused injectable therapies and greater use of specialty biologic drugs. - The report says rising HIV prevalence worldwide is a major driver of market growth. - It cites a May 2024 Minnesota Department of Health report that counted 324 new HIV diagnoses in 2023, up 24% from 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America is expected to hold the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region over the coming years. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

Between the lines: - The market thesis depends less on a broad primary-care drug launch and more on a narrow but persistent clinical need in HIV management. - The emphasis on specialty reimbursement and long-term quality-of-life outcomes suggests pricing and access will matter as much as clinical demand. - The forecast for Asia-Pacific growth implies the company sees future demand expanding beyond the largest current market, not just deepening in North America.

What's next: - The report points to further adoption of injectable peptide therapies and broader use of personalized approaches in HIV-related metabolic care. - Future market growth will likely track diagnosis rates, reimbursement policy changes and the pace of peptide drug development. - The Business Research Company says its updated 2026 materials include new graphics, scoring tools and forecasting dashboards for market tracking.

The bottom line: - Egrifta’s market outlook is tied to rising HIV-related metabolic complications and a broader move toward specialized, patient-specific therapies.